Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
EBS is in the long-term up 53% above S&P in 11 years.
Description: Emergent BioSolutions Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. The Biodefense segment markets BioThrax, an FDA approved vaccine for the prevention of anthrax disease; BAT (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-Equine) for the treatment of suspected or documented exposure to botulinum neurotoxin A, B, C, D, E, F, or G; Vaccinia Immune Globulin Intravenous for counteracting complications associated with the smallpox vaccine; and RSDL (decontamination lotion) to remove and/or neutralize chemical warfare agents from the skin. This segment is also developing Anthrax Immune Globulin Intravenous to treat toxemia associated with inhalational anthrax; NuThrax, an anthrax vaccine in Phase II clinical trials, which is based on BioThrax combined with CPG 7909, an adjuvant licensed from Pfizer Inc.; an
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-42.32%||Sales Growth - Q/Q||-57%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||3.86%||ROE||6.59%||ROI||4.26%|
|Current Ratio||5.05||Quick Ratio||4.03||Long Term Debt/Equity||0.77||Debt Ratio||0.15|
|Gross Margin||74.31%||Operating Margin||12%||Net Profit Margin||7.71%||Dividend Payout Ratio|
|Cash From Financing Activities||11 M||Cash From Investing Activities||-9.08 M||Cash From Operating Activities||-65.87 M||Gross Profit||44.88 M|
|Net Profit||-21.52 M||Operating Profit||-28.31 M||Total Assets||917.85 M||Total Current Assets||405.81 M|
|Total Current Liabilities||80.3 M||Total Debt||251 M||Total Liabilities||379.97 M||Total Revenue||63.63 M|
|High 52 week||73.24||Low 52 week||39.92||Last close||43.62||Last change||-0.93%|
|RSI||53.62||Average true range||1.93||Beta||0.83||Volume||333.02 K|
|Simple moving average 20 days||-0.45%||Simple moving average 50 days||-2.41%||Simple moving average 200 days||-20.53%|
|Performance Week||-2.68%||Performance Month||-0.11%||Performance Quart||-6.58%||Performance Half||-25.55%|
|Performance Year||-18.66%||Performance Year-to-date||-25.68%||Volatility daily||2.28%||Volatility weekly||5.11%|
|Volatility monthly||10.46%||Volatility yearly||36.25%||Relative Volume||180.22%||Average Volume||378.21 K|
|New High||New Low|
2020-06-05 19:39:21 | Emergent BioSolutions Statement on U.S. District Court Decision
2020-06-01 09:34:25 | U.S. awards new $628 million contract to boost output of potential COVID-19 vaccine
2020-06-01 07:50:18 | U.S. awards new $628 mln contract to boost output of potential COVID-19 vaccine
2020-05-30 11:31:03 | Emergent Biosolutions EBS Up 12.9% Since Last Earnings Report: Can It Continue?
2020-05-26 12:05:00 | How to Play Emergent Biosolutions' Continuing Rally
2020-05-18 17:28:32 | Stocks Amid COVID-19 Outbreak: Winners So Far in the Health Industry
2020-05-17 09:31:00 | Is Buying a Basket Loaded With Every Coronavirus Vaccine Stock a Smart Strategy?
2020-05-16 09:04:00 | Is Emergent BioSolutions Stock a Buy?
2020-05-16 07:33:00 | Better Coronavirus Stock: Johnson & Johnson or Emergent BioSolutions?
2020-05-14 11:51:09 | Coronavirus Vaccine Progress Accelerates
2020-05-12 06:00:10 | Emergent BioSolutions to Participate in Virtual Investor Conferences
2020-05-05 08:10:00 | Vaccine Maker Emergent BioSolutions Could Surge Higher in the Months Ahead
2020-05-04 13:21:05 | Emergent EBS Earnings and Revenues Beat Estimates in Q1
2020-05-01 06:45:19 | Edited Transcript of EBS earnings conference call or presentation 30-Apr-20 9:00pm GMT
2020-05-01 04:01:01 | Emergent BioSolutions Inc EBS Q1 2020 Earnings Call Transcript
2020-04-30 18:35:10 | Emergent Biosolutions EBS Surpasses Q1 Earnings and Revenue Estimates
2020-04-30 16:08:53 | Emergent BioSolutions Reports Financial Results for First Quarter 2020
2020-04-29 12:47:04 | Vaxart VXRT to Report Q1 Earnings: What's in the Cards?
2020-04-29 08:48:00 | Is Emergent BioSolutions the Next Hot Coronavirus Stock?
2020-04-24 16:21:16 | Covid Report: How A J&J Vaccine Deal Sent This Biotech Stock Flying
2020-04-24 09:57:00 | Emergent BioSolutions, Johnson & Johnson Sign Virus-Vaccine Accord
2020-04-24 08:37:04 | D.C.-area leaders cautiously turn their eyes toward reopening the economy
2020-04-24 08:32:00 | J&J to pay Emergent $135 million as part of COVID-19 vaccine manufacturing deal
2020-04-23 23:00:33 | J&J strikes deal with Emergent BioSolutions on coronavirus vaccine manufacturing
2020-04-23 12:32:04 | Will Emergent Biosolutions EBS Report Negative Earnings Next Week? What You Should Know
2020-04-22 11:19:03 | Vaxart Up on Pre-Clinical Data on Coronavirus Vaccine Candidates
2020-04-21 16:55:10 | Emergent BioSolutions Appoints Dr. Karen L. Smith as Chief Medical Officer
2020-04-17 14:25:00 | Emergent BioSolutions Is Safe Way to Bet on Covid-19 Vaccines: Portfolio Manager
2020-04-17 06:00:00 | Emergent- Adding Value to Vaccines
2020-04-14 03:08:00 | We Are Dropping Coverage of Erste Group Bank
2020-04-08 06:00:00 | Novavax to start coronavirus vaccine trials sooner than planned
2020-04-05 13:07:00 | Emergent BioSolutions, Eyeing Two Plasma Therapies for Covid-19, Wins Fed's Help
2020-04-03 14:26:03 | These D.C.-area biotech companies are making progress on COVID-19. Here’s the latest.
2020-04-03 07:36:23 | The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO
2020-04-02 14:51:56 | Exclusive: Rockville bio raising $50M, building COVID-19 vaccine — and plotting IPO
2020-04-01 09:42:45 | Tiny Bay Area company aims to win coronavirus vaccine race with a tablet
2020-03-31 17:35:15 | Novavax names manufacturing partner for flu vaccine
2020-03-31 16:05:10 | Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™